disparities by age as an important public health issue. It found cancer survival rates are significantly worse in patients aged over 75 years 5 . Joint research by the National Cancer Equality Initiative and Pharmaceutical Oncology Initiative into geriatric oncology care across Europe and Canada concluded that clinicians use age as proxy for other factors such as comorbidities in making recommendations on cancer treatment. This results in some patients receiving less intensive treatment, solely on the basis of chronological age 6 . Studies into outcomes in specific or single cancers report comparable findings. A US study to assess guideline concordant care in early breast cancer found that the management of patients with an age over 50 years was associated with less guideline concordance, regardless of comorbidity level 7 . EUROCARE 5 reported that poor survival from breast cancer in the UK and Ireland, compared with other European countries, is largely attributed to poor survival in elderly women. This group is reported to be more likely than young patients to receive non-standard treatments, including under utilisation of surgery, failure to perform standard assessments and failure to give radiotherapy after conservative surgery 5 . There is evidence of suboptimal management of older patients with other cancers including ovarian, colon and prostate cancer 6, 8, 9 . Eighty percent of patients aged 40-49 years with ovarian cancer had resection compared with less than half of those aged over 50 years 6 . Older men with prostate cancer tend to have more aggressive disease but a minority receive curative chemotherapy; despite evidence that chemotherapy confers survival and quality-of-life benefit. Two thirds of deaths from prostate cancer are in men over 75 years
9 . Other studies demonstrate that elderly patients have not benefitted from advances in cancer management. Improvements in outcomes achieved for the patients below 75 have not been matched by that in the geriatric population. For example, analysis of survival rates in Acute Myeloid Leukaemia between 1977 and 2006 demonstrated that developments in treatment improved overall survival rates; however, survival rates in the 85-year group remained unchanged over 3 decades 10 .
Current evidence base in geriatric oncology
Historically, older persons, particularly those at the extremes of age, have been under represented in clinical cancer trials 11 . In recent years, there has been a move to address this evidence gap.
Recognising shortcomings in the field the International Society for Geriatric Oncology (ISGO) set up task forces to review current best practice and establish future research priorities. Most recently published recommendations for the use of radiotherapy and update of the management of non-small-cell lung cancer in elderly patients, with a forthcoming update on the management of colorectal and prostate cancer, are expected later this year 12,13 . The number of trials specifically enrolling geriatric patients has increased. Data have demonstrated that fit elderly cancer patients are able to tolerate and gain survival advantage from the same treatments offered to their younger counterparts. For example, IFCT 0501 trial compared carboplatin and weekly paclitaxel double chemotherapy with monotherapy in elderly patients with advanced non-small-cell lung cancer (performance status 1-2 aged 70-89 years). Previously, monotherapy was the only recommended regimen for patients over 70 years of age. The double therapy group did experience more side effects, however, had meaningfully increased overall survival compared with the monotherapy group (44% and 22% survival at 1 year, respectively) 14 . Conversely, frailer patients may not tolerate aggressive cancer treatment, which is currently recognised as best practice. For this group, research into the development of new approaches and recognition of which regimens are best tolerated is important. Trials in breast cancer care have demonstrated that very high-risk surgical candidates may undergo resection under local or regional anesthesia 15, 16 . New approaches to radiotherapy including advances in planning and delivery have shown to result in better tolerance and reduced healthy tissue damage widening its use 12 . Progress has been made but ongoing research is needed. In a joint position paper, the European Organisation for Research and Treatment of Cancer, International Society for Geriatric Oncology and the Alliance for Clinical trials set out standards for future trials in geriatric oncology. Key points include the need for trials without upper age limit, flexible design and the use of a comparable form of geriatric assessment across studies 17 .
Geriatric assessment
Management of patients with cancer should be guided by an adequate evaluation of global health status. The National Comprehensive Cancer Network (NCCN) and ISGO recommend some form of geriatric assessment in all patients aged 70 years 18,19 . Part of this adequate evaluation should include a form of geriatric assessment to minimise the discrepancy of treatment between age groups. The comprehensive geriatric assessment (CGA) tool involves a multidisciplinary approach. Factors including evaluation of comorbidities, functional status, social status, cognitive function, nutritional status, psychological well being, polypharmacy and geriatric syndromes are evaluated and incorporated into the assessment tool. Trial data have shown that CGA detects previously unrecognised geriatric problems in over 50% of patients; predict prognosis and treatment toxicity; and allow adaption that results in improved quality of life, overall survival and compliance. Despite the evidence, CGA is not widely used in clinical practice. 
